Skip to main content
OpenTrials
Completed

NCT Number: NCT00925041

Clinical Evaluation of the Vedera KXS for the Treatment of Spherical Myopia

The objective of this clinical investigation is to evaluate the safety and efficacy of the Vedera KXS in sighted eyes for the correction of spherical myopia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beyoglu Eye Research and Education Hospital

Istanbul, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be undergoing surgery for the correction of myopia
  • Intended treatment from -0.5 to -6.0 D of spherical myopia
  • Must have 0.50 D or less astigmatic component.
  • Must have bilateral physiologic myopia
  • BSCVA of 20/25 or better in each eye
  • Must have had a stable refraction (0.5 D or less change in spheroequivalent) for at least one year, objectively documented (by previous clinical records, eyeglass prescriptions, etc. over one year old)
  • Patients who are contact lens wearers must have hard or gas permeable lenses discontinued for two weeks and soft lenses discontinued for three days prior to the preoperative evaluation
  • Must be at least 18 years of age
  • Corneal topography must be normal, as judged by the investigator
  • Must have a minimal corneal thickness of 475 microns
  • Must sign a written Informed Consent form acknowledging their awareness of their participation in this study, the alternative treatments available, the risks involved, and the investigative nature of the procedure, and other issues which conform to the standard of care for Informed Consent practices
  • Must be willing and capable of returning for scheduled follow-up examinations for 24 months after treatment

Exclusion criteria

  • Patients who are unable or unwilling to sign the informed consent form.
  • Anterior segment pathology
  • Residual, recurrent or active ocular disease
  • Patients who have undergone previous intraocular or corneal surgery involving the stroma in the eye to be operated.
  • History of herpes keratitis
  • Patients with diagnosed autoimmune disease, systemic connective tissue diseases or atopic syndrome, diabetes mellitus, or taking systemic medications (i.e., corticosteroids or antimetabolites) likely to affect wound healing.
  • Irregular central keratometry/topography readings with irregular topography patterns or keratometry mires, including signs of keratoconus.
  • Patients with known sensitivity to study medications.
  • Intraocular pressure of > 23 mm Hg by Goldmann applanation tonometry, a history of glaucoma, or glaucoma suspect.
  • Women who are pregnant or nursing or who plan to become pregnant over the course of their participation in this investigation.
  • Participation in other ophthalmic clinical trials during this clinical investigation.

Treatment and study plan

Vedera KXS

Device

one treatment with the Vedera KXS

Primary outcomes

  1. UCVA 20/40 or better

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Glaukos Corporation

Industry

Registry information

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
Jun 19, 2009
Registry last updated
Apr 26, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.